Immune evasion is a major obstacle for cancer treatment. Common mechanisms of evasion
include impaired antigen presentation caused by mutations or loss of heterozygosity of the …

Major histocompatibility complex class I (MHC-I) is a key molecule in anti-tumor adaptive
immunity. MHC-I is essential for endogenous antigen presentation by cancer cells and …

Macroautophagy (hereafter referred to as autophagy) is a process in which organelles
termed autophagosomes deliver cytoplasmic constituents to lysosomes for degradation …

Antineoplastic chemotherapies are particularly efficient when they elicit immunogenic cell
death, thus provoking an anticancer immune response. Here we demonstrate that …

Macroautophagy (hereafter autophagy) degrades and recycles intracellular components to
sustain metabolism and survival during starvation. Host autophagy promotes tumor growth …

DNA mismatch repair-deficient (MMR-d) cancers present an abundance of neoantigens that
is thought to explain their exceptional responsiveness to immune checkpoint blockade …

Pancreatic ductal adenocarcinoma (PDAC) is considered non-immunogenic, with trials
showing its recalcitrance to PD1 and CTLA4 immune checkpoint therapies (ICTs). Here, we …

The ability of the immune system to eliminate and shape the immunogenicity of tumours
defines the process of cancer immunoediting. Immunotherapies such as those that target …

Single-agent immunotherapy has achieved limited clinical benefit to date in patients with
pancreatic ductal adenocarcinoma (PDAC). This may be a result of the presence of a …

Although the main focus of immuno-oncology has been manipulating the adaptive immune
system, harnessing both the innate and adaptive arms of the immune system might produce …